FARMINGDALE, N.Y., March 16, 2011 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced a definitive agreement for non-exclusive distribution, with the exception of certain selected accounts, of the BoneScalpel Ultrasonic Bone Cutting System in the United States with Aesculap, Inc., which replaces a prior exclusive distribution agreement between the parties. The agreement is limited to clinical applications relative to the spine and cranium.
In response, Misonix will begin the marketing, sales, distribution and service of the BoneScalpel in the U.S., effective immediately, utilizing its 75 person surgical sales organization, which markets direct to hospitals and free-standing surgery centers. In addition to spine and cranial applications, the Misonix sales organization will market the product for a broad range of maxiofacial and other small bone clinical applications.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.
"Misonix is excited about adding BoneScalpel to our focused, domestic sales organization. With this Agreement, Misonix will now be selling the BoneScalpel worldwide," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Over time, we anticipate significant margin improvement and sales growth by allowing our proprietary sales organization the opportunity to sell another one of our key products under the Misonix label."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
SOURCE Misonix, Inc.